Nexavar Related Published Studies
Well-designed clinical trials related to Nexavar (Sorafenib)
Sorafenib or placebo with either gemcitabine or capecitabine in patients with
HER-2-negative advanced breast cancer that progressed during or after
bevacizumab. [2013]
Phase III trial of carboplatin and paclitaxel with or without sorafenib in
metastatic melanoma. [2013]
AMG 386 in combination with sorafenib in patients with metastatic clear cell
carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2
study. [2012]
Sorafenib in locally advanced or metastatic breast cancer. [2012]
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme
for HCV-related intermediate-stage hepatocellular carcinoma: a randomized
clinical trial. [2012]
Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. [2011.12]
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. [2011.08.11]
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. [2011.07.01]
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. [2011.07]
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. [2011.07]
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. [2011.06.20]
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. [2011.06]
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. [2011.04.12]
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. [2011.03.01]
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer]. [2011.03]
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. [2011.02]
Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. [2011.01]
Rationale and design of decision: a double-blind, randomized, placebo-controlled
phase III trial evaluating the efficacy and safety of sorafenib in patients with
locally advanced or metastatic radioactive iodine (RAI)-refractory,
differentiated thyroid cancer. [2011]
Randomized phase II study of bevacizumab in combination with chemotherapy in
previously untreated extensive-stage small-cell lung cancer: results from the
SALUTE trial. [2011]
Sorafenib: activity and clinical application in patients with hepatocellular
carcinoma. [2011]
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? [2010.12]
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. [2010.11.17]
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. [2010.10.01]
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. [2010.09]
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. [2010.09]
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. [2010.08]
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. [2010.07]
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. [2010.05.25]
Sorafenib for the treatment of advanced hepatocellular carcinoma. [2010.05]
Incidence of brain metastases in renal cell carcinoma treated with sorafenib. [2010.05]
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. [2010.04.10]
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. [2010.03]
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. [2010.02.20]
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. [2010.02]
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. [2010.01.01]
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. [2010.01]
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. [2010]
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced
hepatocellular carcinoma: a randomized trial. [2010]
Association of skeletal muscle wasting with treatment with sorafenib in patients
with advanced renal cell carcinoma: results from a placebo-controlled study. [2010]
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. [2009.07.10]
Sorafenib tosylate in advanced kidney cancer: past, present and future. [2009.07]
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. [2009.06.10]
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. [2009.03.10]
[Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)] [2009.03]
Sorafenib for the treatment of unresectable hepatocellular carcinoma. [2009.01]
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. [2009.01]
Sorafenib: a review of its use in advanced hepatocellular carcinoma. [2009]
Sorafenib for the treatment of unresectable hepatocellular carcinoma. [2008.12]
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. [2008.11.26]
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. [2008.10.15]
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. [2008.10.01]
Sorafenib in advanced hepatocellular carcinoma. [2008.07.24]
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. [2008.05.01]
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. [2008.04]
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. [2008.02.06]
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. [2008.01.15]
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. [2008.01.15]
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. [2007.11.26]
Sorafenib TARGET trial results in Spanish patients. [2007.10]
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. [2007.09]
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. [2007.06]
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. [2007.05]
Sorafenib in advanced clear-cell renal-cell carcinoma. [2007.01.11]
Randomized discontinuation trial of sorafenib (BAY 43-9006). [2006.10]
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. [2006.09.04]
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. [2006.06.01]
Well-designed clinical trials possibly related to Nexavar (Sorafenib)
Chemoembolization for hepatocellular carcinoma. [2012]
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2011.12]
Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. [2011.10.01]
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. [2011.10]
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. [2011.06]
Targeted therapies for thyroid tumors. [2011.04]
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. [2011.01]
Management of adverse events associated with the use of everolimus in patients
with advanced renal cell carcinoma. [2011]
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup
analysis of Japanese patients from RECORD-1. [2011]
Pazopanib in renal cell carcinoma. [2010.12.15]
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. [2010.09.15]
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. [2010.08.10]
[Hepatocellular carcinoma] [2010.07]
Pazopanib in renal cell carcinoma. [2010]
Everolimus: in advanced renal cell carcinoma. [2009.10.22]
Role of everolimus in the treatment of renal cell carcinoma. [2009.10]
Lessons learned from independent central review. [2009.01]
Everolimus: in advanced renal cell carcinoma. [2009]
New pharmacological developments in the treatment of hepatocellular cancer. [2009]
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.09]
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. [2008.08.09]
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. [2008.06.20]
Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. [2008]
Mechanisms of hypertension associated with BAY 43-9006. [2006.03.20]
Kinase inhibition with BAY 43-9006 in renal cell carcinoma. [2004.09.15]
Other research related to Nexavar (Sorafenib)
Treatment efficacy differences of sorafenib for advanced hepatocellular
carcinoma: a meta-analysis of randomized clinical trials. [2015]
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma:
results of a randomized phase III trial. [2015]
Combination of letrozole, metronomic cyclophosphamide and sorafenib is
well-tolerated and shows activity in patients with primary breast cancer. [2015]
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular
carcinoma: a systematic review and meta-analysis. [2014]
Sorafenib in liver function impaired advanced hepatocellular carcinoma. [2014]
Management of common adverse events in patients treated with sorafenib: nurse and
pharmacist perspective. [2014]
A randomized multicenter phase II trial on the efficacy of a hydrocolloid
dressing containing ceramide with a low-friction external surface for hand-foot
skin reaction caused by sorafenib in patients with renal cell carcinoma. [2014]
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a
randomized phase III trial. [2013]
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone
in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. [2013]
Tivozanib versus sorafenib as initial targeted therapy for patients with
metastatic renal cell carcinoma: results from a phase III trial. [2013]
|